We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Probiotix Health Plc | AQSE:PBX | Aquis Stock Exchange | Ordinary Share | GB00BLNBFR86 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.00 | 3.00 | 6.00 | 5.90 | 4.163 | 5.00 | 89,049 | 15:29:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jun 2021 to Jun 2024
TIDMPBX
RNS Number : 5760I
Probiotix Health PLC
19 April 2022
ProBiotix Health plc
("ProBiotix Health" or the "Company")
Change of registered office
ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that it has changed its registered address to: First Floor, Zucchi Suite, Nostell Business Estate, Wakefield, WF4 1AB with immediate effect.
All formal notices and general correspondence should be sent to the new address.
For further information, please contact:
Probiotix Health plc Contact via Walbrook below Stephen O'Hara, Chief Executive Peterhouse Capital Limited Tel: 020 7469 0930 Mark Anwyl (AQSE Corporate Adviser) Duncan Vasey (Broker) Walbrook PR Ltd Mob: 07876 741 001 or probiotix@walbrookpr.com Anna Dunphy
About ProBiotix Health plc
ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.
ProBiotix Health's cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 ("LP-LDL(R)), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXGZGMDRLNGZZG
(END) Dow Jones Newswires
April 19, 2022 04:08 ET (08:08 GMT)
1 Year Probiotix Health Chart |
1 Month Probiotix Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
